Kidney injury during VEGF inhibitor therapy

Netherlands Journal of Medicine

Volumn 70, Issue 6, 2012, Pages 267-271

  Den Deurwaarder, E S G ^a   Desar, I M E ^b   Steenbergen, E J ^c   Mulders, P F ^d   Wetzels, J F M ^e   Van Herpen, C M L ^b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b Departments of Medical Oncology   (Netherlands)

^c Departments of Pathology   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti VEGF therapy; Cediranib; FSGS; Kidney toxicity

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CEDIRANIB; CREATININE; EVEROLIMUS; FUROSEMIDE; PAMIDRONIC ACID; PAZOPANIB; PRAVASTATIN; PREDNISONE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN A;

ACUTE KIDNEY FAILURE; ADULT; ANOREXIA; APATHY; ARTICLE; CASE REPORT; DIARRHEA; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; ELECTRON MICROSCOPY; FIBROSING ALVEOLITIS; FLUID RETENTION; FOCAL GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOFLUORESCENCE; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY INJURY; LOW DRUG DOSE; MALAISE; MALE; META ANALYSIS (TOPIC); NEPHROTIC SYNDROME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEINURIA; SYSTEMATIC REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; KIDNEY;

GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY; NEPHROTIC SYNDROME; PROTEINURIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84871691291     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gurevich F, Perazella MA. Renal Effects of Anti-angiogenesis Therapy: Update for the Internist. Am J Med. 2009;122:322-328.
2. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186-193.
3. van Zyl-Smit R, Firth JC, Duffield M, Marais AD. Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant. 2004;19:3176-3179.
4. Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008;100:282-284.
5. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48:9-17.
6. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278:12605-12608.
7. Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009;1;15:6250-6257.
8. Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol. 2009;27:6152-6159.
9. Yamamoto N, Tamura T, Yamada K, et al. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009;64:1165-1172.
10. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
11. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136.
12. Frangié C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol. 2007;8:177-178.
13. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-2191.
14. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of c apecitabine c ompared w ith b evacizumab p lus c apecitabine i n patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-799.
15. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007;49:e23-e29.
16. Izzedine H, Brocheriou I, Deray G, Rixe O. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant. 2007;22:1481-1482.
17. Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol. 2007;3:287-293.
18. Stokes MB, Erazo MC, D'Agati VD. Glomerular disease related to anti-VEGF therapy. Kidney Int. 2008;74:1487-1491.
19. Barakat RK, Singh N, Lal R, Verani RR, Finkel KW, Foringer JR. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother. 2007;41:707-710.
20. Leung N, Saucier NA, Zeldenrust SR, Gunderson HD, Cornell LD. Acute renal failure after treatment with sunitinib in a patient with multiple myeloma. Nephrol Dial Transplant Plus. 2009;2:292-294.
21. Bollée G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009;24:682-685.
22. Zhao J, Li H, Wang M. Acute renal failure in a patient receiving anti-VEGF therapy for advanced non-small cell lung cancer. J Thorac Oncol. 2009;4:1185-1187.
23. Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, Selgas R. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant. 2010;25:1001-1003.
24. Izzedine H, Brocheriou I, Rixe O, Deray G, et al. Interstitial nephritis in a patient taking sorafenib. Nephrology Dialysis Transplant. 2007;22:2411.
25. Müller-Deile J, Bröcker V, Grünwald V, et al. Renal side effects of VEGF-blocking therapy. Nephrol Dial Transplant Plus. 2010; 3:172-175
26. Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol. 2011;Oct 1. [Epub ahead of print]
27. Stylianou K, Lioudaki E, Papadimitraki E, et al. Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Nephrol Dial Transplant. 2011;26:1742-1745.
28. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788-1795.
29. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707-716.
30. Schrijvers, BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65:2003-2017.
31. Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs. 2009;20:81-82.
32. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando). 2008;22:125-130.